Solid Tumors Using Ixabepilone and Dasatinib

MedStar Health

Status and phase: Completed; Phase 1

Conditions: Solid Tumor

Treatments: Drug: ixabepilone; Drug: Dasatinib

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00717704

WCI-2007-528

Details and patient eligibility

About

Patients are being asked to take part in this study because they have been diagnosed with an advanced solid tumor that is not responding to standard treatments. This study will find the highest dose of ixabepilone and dasatinib in combination that can be given without causing severe side effects.

Both ixabepilone and dasatinib have individually been tested in many (several thousand) patients, however the combination of the two drugs has not yet been tested in humans.

All patients who will take part in this study will receive combined drug therapy of dasatinib and ixabepilone. Dasatinib is a pill that is taken by mouth. Ixabepilone is a medicine that will be given by vein (IV).

All participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily.

Enrollment: 19 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a solid tumor malignancy that is metastatic or locally advanced/unresectable
• Progression through standard therapy
• Histological documentation of cancer
• Must be off prior chemotherapy or radiation therapy for at least 3 weeks
• Must have adequate organ and marrow function prior to the start of study treatment as defined by the protocol
• Must be able to swallow oral medication (dasatinib must be swallowed whole)
• Must be available for protocol-required follow-up

Exclusion criteria

• Patients with a malignancy (other than the one treated in this study) which required radiotherapy or systemic therapy within the past 5 years
• Symptomatic brain metastasis that is either untreated or uncontrolled by surgery and or radiotherapy
• A known, prior, severe (NCI CTC Grade 3/Grade 4) history of hypersensitivity reaction to a drug formulated in Cremophor (polyoxyethylated castor oil)
• A serious, uncontrolled medical disorder or active infection including pericardial or pleural effusion of any grade,uncontrolled or significant cardiovascular disease,a bleeding disorder.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

19 participants in 1 patient group

1

Experimental group

Description:

All participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily. All participants will receive the study drugs at a baseline dose. If the side effects are minimal and tolerable, the next cycle of study drugs will be given at same dosage. If side effects are intolerable, then the dose will be lowered.

Treatment:

Drug: Dasatinib

Drug: ixabepilone